US · Healthcare · Biotechnology
EPS came in at -0.97 against a street estimate of -1.08 — a beat of 10.2%.
Analysts rate Forte Biosciences Inc a strong buy (4 buy, 0 hold, 0 sell out of 4) with an average price target of $73.00.
| Fund | Stake |
|---|---|
| Federated Hermes Inc | 9.94% |
| Fred Alger Management, LLC | 6.00% |
| Orbimed Advisors LLC | 5.64% |
| HHG PLC | 5.60% |
| Affinity Asset Advisors, LLC | 5.40% |
| MPM Oncology Impact Management LP | 4.65% |
| TCG Crossover Management, LLC | 4.33% |
| Adage Capital Partners Gp LLC | 3.30% |
| Document | Date |
|---|---|
| Acquisition completed · Q3 2026 FORTE BIOSCIENCES, INC. - FORM 8-K SUMMARY HEADLINE NUMBERS • Acquisition Price: $77.00 per share in cash • Shares Tendered: 19,894,879 shares (87.1 | 2026-08-27 |
| Quarterly report · Q2 2026 FORTE BIOSCIENCES, INC. – 10-Q SUMMARY (JUNE 30, 2026) HEADLINE NUMBERS • Cash position: $49.6 million cash + $148.8 million short-term investments | 2026-08-12 |
| Material agreement · Q3 2026 FORTE BIOSCIENCES, INC. - 8-K SUMMARY HEADLINE NUMBERS • Acquisition Price: $77.00 per share in cash, net to sellers • Acquirer: argenx BV, a Belgia | 2026-07-27 |
| Reg FD disclosure · Q3 2026 FORTE BIOSCIENCES, INC. - DOCUMENT SUMMARY HEADLINE NUMBERS • Company: Forte Biosciences, Inc. (NASDAQ: FBRX) • Report Date: July 9, 2026 • Headquar | 2026-07-09 |
| Board / officer change · Q2 2026 FORTE BIOSCIENCES, INC. - 8-K SUMMARY HEADLINE NUMBERS • Annual meeting held May 29, 2026 with 17,766,034 shares represented out of 20,478,817 outst | 2026-06-02 |
| Quarterly report · Q1 2026 FORTE BIOSCIENCES, INC. – 10-Q SUMMARY (Q1 2026) HEADLINE NUMBERS • Cash position: $58.2 million as of March 31, 2026 (down from $77.0 million at De | 2026-05-11 |
| Proxy statement · Q2 2026 FORTE BIOSCIENCES, INC. – 2026 PROXY STATEMENT SUMMARY CEO COMPENSATION • Paul A. Wagner, Ph.D. (CEO, Chairman, President): Total compensation figur | 2026-04-29 |
| Annual report FY2025 FORTE BIOSCIENCES, INC. – 10-K SUMMARY FOR RETAIL INVESTORS HEADLINE NUMBERS • Market capitalization: $157.0 million as of June 30, 2025 • Shares ou | 2026-03-31 |
Readable in the app.
| Action | Detail | Date |
|---|---|---|
| Split | 1 : 25 effective Aug 28, 2024 | 2024-08-28 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Forte Biosciences Inc — free to start.
Google PlayApp StoreData updated 2026-09-18.